Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.74 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ESRRA | P11474 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181110 | 0.87 | AR (0.64) | ARPGRPOLBGAASLC22A12 | |
| SCHEMBL5501269 | 0.87 | AR (0.57) | ARPGRPOLBGAASLC22A12 | |
| SCHEMBL4168098 | 0.87 | AR (0.65) | ARPGRPOLBGAASLC22A12 | |
| SCHEMBL4182051 | 0.86 | AR (0.59) | ARPGRSLC22A12ESRRA | |
| SCHEMBL753907 | 0.86 | AR (0.75) | ARPGRPOLBGAASLC22A12 | |
| SCHEMBL13890551 | 0.86 | AR (0.75) | ARPOLBGAASLC22A12 | |
| SCHEMBL4175953 | 0.85 | AR (1.00) | ARPGRPOLBGAASLC22A12 | |
| SCHEMBL4178475 | 0.84 | AR (0.68) | ARPGRPOLBGAASLC22A12 | |
| SCHEMBL4172657 | 0.84 | AR (0.68) | ARPGRPOLBGAASLC22A12 | |
| SCHEMBL4181860 | 0.84 | AR (0.67) | ARPGRSLC22A12ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | claimed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105349-A1 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1781280-A2 | ANDROGEN MODULATORS | Warner-Lambert Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018723-A2 | ANDROGEN MODULATORS | WARNER-LAMBERT COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105349-A1 | ANDROGEN MODULATORS | AR, NR5A1, SHBG | AR 1/4885PGR 48/4885POLB 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.